Progress in the correlation of postoperative cognitive dysfunction and Alzheimer's disease and the potential therapeutic drug exploration

Dong‐Qin Chen,Xu Fang,Zhao‐Qiong Zhu

DOI: https://doi.org/10.1002/ibra.12040

2022-05-19

Ibrain

Abstract:Postoperative cognitive dysfunction (POCD) is a decrease in mental capacity that can occur days to weeks after a medical procedure and may become permanent and rarely lasts for a longer period of time. With the continuous development of research, various viewpoints in academic circles have undergone subtle changes, and the role of anesthesia depth and anesthesia type seems to be gradually weakened; Alzheimer's disease (AD) is a latent and progressive neurodegenerative disease in the elderly. The protein hypothesis and the synaptic hypothesis are well‐known reasons. These changes will also lead to the occurrence of an inflammatory cascade. The exact etiology and pathogenesis need to be studied. The reasonable biological mechanism affecting brain protein deposition, neuroinflammation, and acetylcholine‐like effect has a certain relationship between AD and POCD. Whereas there is still further uncertainty about the mechanism and treatment, and it is elusive whether POCD is a link in the continuous progress of AD or a separate entity, which has doubts about the diagnosis and treatment of the disease. Therefore, this review is based on the current common clinical characteristics of AD and POCD, and pathophysiological research, to search for their common points and explore the direction and new strategies for future treatment. There is a correlation between postoperative cognitivedysfunction and Alzheimer's disease in clinical symptoms, cerebrospinal fluid markers, and the expression of some inflammatory factors, and in mechanisms, the deposition of A‐β and tau proteins, and cholinergic system disorders, synaptic plasticity plays an important role in addressing these commonalities, anti‐inflammatory, clearing A‐β and tau proteins, maintaining the balance of the intestinal flora, exosomes, and even microRNAs are potential therapeutic targets.